Congressional Budget OfficeSkip Navigation
Home Red Bullet Publications Red Bullet Cost Estimates Red Bullet About CBO Red Bullet Press Red Bullet Careers Red Bullet Contact Us Red Bullet Director's Blog Red Bullet   RSS
PDF

April 23, 2001
 

Honorable Don Nickles
Assistant Majority Leader
United States Senate
Washington, DC 20510

Dear Senator:

At your request, the Congressional Budget Office has prepared the attached table showing the ultimate average effect on premiums for employer-sponsored health insurance of S. 283, the Bipartisan Patient Protection Act of 2001, as introduced on February 7, 2001. We estimate that enacting the bill would ultimately increase the premiums for employer-sponsored health plans by an average of 4.2 percent.

Among its other provisions, the bill would require a group health plan or issuer of health insurance to pay routine patient costs in clinical trials approved and funded by certain organizations, including the Food and Drug Administration (FDA). The FDA does not fund clinical trials. The estimate assumes plans would be required to pay routine patient costs in clinical trials approved by the FDA.

It is worth noting that there have been significant changes in the environment, and hence our baseline, since last year. For example, this estimate reflects recent court decisions that decrease the likelihood that state laws regulating the appeals processes of health plans are preempted by current federal law.

I hope this information is helpful to you. The CBO staff contact is Tom Bradley.

Sincerely,

Dan L. Crippen
Director
 

Attachment
 
cc: Honorable James M. Jeffords, Chairman, Senate Committee on Health, Education, Labor and Pensions
  Honorable Edward M. Kennedy, Ranking Member
  Honorable John McCain

 


 

ESTIMATED ULTIMATE EFFECT OF S. 283, THE BIPARTISAN PATIENT PROTECTION ACT OF 2001, ON PREMIUMS FOR EMPLOYER-SPONSORED HEALTH INSURANCE (In percent)
Provision Increase in Premiums

Subtitle A--Grievances and Appeals  
  Utilization review activities 0.2  
  Procedures for initial claims and prior authorization a  
  Internal and external appeals 1.0  
 
Subtitle B--Access to Care  
  Consumer choice 0.1  
  Choice of health care professional a  
  Access to emergency care 0.4  
  Access to specialty care 0.3  
  Access to obstetric and gynecological care 0.1  
  Access to pediatric care a  
  Continuity of care 0.3  
  Access to needed drugs a  
  Clinical trials 0.8  
 
Subtitle C--Access to Information 0.1  
 
Subtitle D--Protecting the Doctor-Patient Relationship a  
 
Subtitle E--Definitions  
  Coverage of limited scope plans a  
 
Title III--Availability of Civil Remedies 0.8  
 
Title IV--Women's Health and Cancer Rights 0.2  
 
  Total 4.2  

SOURCE: Congressional Budget Office.
a. Less than 0.05 percent

April 23, 2001